interleukin-6
interleukin-6
Overview
Interleukin-6 (IL-6) is a multifunctional cytokine that plays a critical role in the immune response, inflammation, and hematopoiesis. It is produced by various cell types, including T cells, B cells, macrophages, and fibroblasts, and is involved in the regulation of immune responses, acute phase reactions, and the differentiation of immune cells. IL-6 exerts its effects primarily through the activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, particularly STAT3, which mediates its pro-inflammatory and anti-inflammatory effects. Dysregulation of IL-6 has been implicated in various pathological conditions, including autoimmune diseases, chronic inflammatory disorders, and cancer, making it a significant target for therapeutic interventions.
Focus of Latest Publications
Recent studies have highlighted the importance of IL-6 in various clinical contexts and its potential as a therapeutic target. For instance, a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma patients found that lower baseline levels of IL-6 were associated with higher survival rates (PMID: 41732954). This suggests that IL-6 may serve as a prognostic biomarker in cancer immunotherapy.
In the context of diabetic wound healing, a study demonstrated that the topical delivery of miR-497 using cationized gelatin/sodium alginate coacervates significantly suppressed pro-inflammatory cytokine expression, including IL-6, thereby promoting cell migration and healing (PMID: 41934393). Similarly, another investigation into the effects of artificial mitochondria on osteoarthritis revealed that treatment led to the suppression of inflammatory pathways, including IL-6, while enhancing extracellular matrix biosynthesis (PMID: 41816316).
IL-6 has also been implicated in the pathogenesis of various diseases. For example, in a study on peripartum cardiomyopathy, elevated levels of IL-6 were associated with left ventricular dysfunction and poor prognosis (PMID: 41905945). Additionally, research on the modulation of inflammatory responses in macrophages indicated that certain compounds could significantly downregulate IL-6 expression in response to lipopolysaccharide (LPS) stimulation (PMID: 42178365).
Moreover, IL-6 has been identified as a core target in network pharmacology studies investigating the mechanisms of various therapies, including those for ulcerative colitis and diabetic nephropathy (PMID: 42089391, 42009593). The cytokine's involvement in inflammatory processes has also been noted in studies examining the effects of omega-3 fatty acids and other anti-inflammatory treatments (PMID: 42045798).